Model-Based Economic Analyses of Haemophilia from a Societal Perspective: A Scoping Review [0.03%]
基于模型的经济学分析：血友病社会视角下的综述研究
Amr A El-Sayed,Nancy S Bolous
Amr A El-Sayed
Introduction: Haemophilia imposes substantial lifelong humanistic and economic burdens, necessitating economic evaluations that adopt a societal perspective and comprehensively capture all relevant costs. Given the rarity...
Estimation of Health Utility Values for Eosinophilic Granulomatosis With Polyangiitis [0.03%]
估计肉芽肿性多血管炎的健康效用值
Bhovina Buguth,Jacqui Bernarde,Daniel Aggio et al.
Bhovina Buguth et al.
Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare autoimmune disease, characterised by inflammation of small- to medium-sized blood vessels, however, it remains poorly described in the literature....
Cost-Effectiveness Analysis of Etrasimod Compared With Biologic Therapies for the Treatment of Patients with Moderately-to-Severely Active Ulcerative Colitis in Spain [0.03%]
西班牙对中至重度活动性溃疡性结肠炎患者使用艾替洛尔与生物制剂治疗的成本效益分析
Iago Rodríguez-Lago,Fernando Muñoz Núñez,Alfredo J Lucendo et al.
Iago Rodríguez-Lago et al.
Background: Etrasimod (2 mg orally, once daily) is a novel advanced therapy (AT) for patients aged 16 years and older, with moderately-to-severely active ulcerative colitis (UC). This cost-effectiveness analysis compared ...
Cost of Chronic Heart Failure Among Adult Europeans-A Systematic Literature Review [0.03%]
欧洲成人慢性心力衰竭的经济负担——系统评价
Alexandra Mincă,Claudiu C Popescu,Dragoş I Mincă et al.
Alexandra Mincă et al.
Background: Chronic heart failure (CHF) imposes a substantial and growing burden on healthcare systems. While individual studies have evaluated the cost of CHF, variability in reporting standards and regional data gaps li...
Cost-Effectiveness Analysis of Abrocitinib Compared with Dupilumab for Adolescents With Severe Atopic Dermatitis in Spain [0.03%]
与度普利尤单抗相比，阿布昔替尼治疗西班牙中重度特应性皮炎青少年的成本效益分析
Rosa María Romero Jiménez,Pedro Herranz Pinto,Minia Campos Domínguez et al.
Rosa María Romero Jiménez et al.
Health Utility Decrement of Injection Treatment-Related Attributes Using Time Trade-Off Among Type 2 Diabetes Patients: A Vignette-Based Study [0.03%]
基于情节的2型糖尿病患者注射治疗相关属性时间贸易-off研究健康效用减量
Xinran Liu,Chang Luo,Shitong Xie et al.
Xinran Liu et al.
Objectives: To identify health utility decrements of injection treatment-related attributes among patients with type 2 diabetes mellitus (T2DM) in China. ...
Venetoclax in Combination with Obinutuzumab in Previously Untreated Fit Patients with Chronic Lymphocytic Leukemia: A Canadian Cost-Utility Analysis [0.03%]
venetoclax联合奥比乌马布单抗治疗初治且适合移植的慢性淋巴细胞白血病患者的加拿大成本效用分析
Gijs van de Wetering,Carolyn Owen,Versha Banerji et al.
Gijs van de Wetering et al.
Background/objective: Chronic lymphocytic leukemia (CLL) is the most common lymphoproliferative disorder diagnosed in Canada and is associated with a significant economic burden. This study evaluates the cost effectivenes...
Cost-Effectiveness Modelling of Multiple System Atrophy for Early Health Technology Assessment [0.03%]
帕金森综合症的低成本模型构建及早期医疗技术评估
Tobias Sydendal Grand,Shijie Ren,Praveen Thokala et al.
Tobias Sydendal Grand et al.
Background and objectives: Multiple system atrophy is a neurodegenerative and rapidly progressing disease. Although symptoms often overlap, diagnostic criteria define two motor phenotypes: cerebellar and Parkinsonian. Lit...
The Consistency and Transferability of Economic Evaluations of Disease-Modifying Treatments for Multiple Sclerosis: Analysis of Cost-Effectiveness Assessments from Australia, England, Canada and Scotland [0.03%]
澳大利亚、英格兰、加拿大和苏格兰关于多发性硬化症修正治疗的成本效益评估的连贯性和可转移性分析
Xiang Wang,Feili Zhao,David Newby et al.
Xiang Wang et al.
Objective: Our study examines the consistency and transferability of cost-effectiveness values, specifically the incremental cost-effectiveness ratio (ICER), focusing on several disease-modifying therapies (DMTs) for rela...
An Introduction to Costing and the Types of Costs Used within Health Economic Studies [0.03%]
卫生经济学研究中的成本核算及各类成本介绍
Hugo C Turner,Juan Carlos Rivillas-Garcia,Shankar Prinja et al.
Hugo C Turner et al.
The number of published health economic analyses, especially economic evaluations, has rapidly expanded globally since the 1990s, and costs are an essential component of such studies. Cost is a general term that refers to the value of the r...